LWCFA
AMAG

Loring Wolcott & Coolidge Fiduciary Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-62
Closed -$1K – 911
2017
Q3 		$1K Buy
+62
New +$1.16K ﹤0.01% 764

Other funds holding AMAG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's AMAG Position: Q4 2017 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q4 2017, closing a stake of 62 shares — an estimated $1K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in AMAG in Q3 2017 and held it in 1 quarter. The position peaked at $1K in Q3 2017. 170 funds tracked by Wall St. Rank hold AMAG as of Q4 2017.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining AMAG Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 62 AMAG Pharmaceuticals shares in Q4 2017, an estimated $1K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in AMAG Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors's AMAG Pharmaceuticals position peaked at $1K in Q3 2017.
  • 170 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2017.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2017, filed 8 Feb 2018.